These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23555949)

  • 1. Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.
    Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Fukamachi T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
    PLoS One; 2013; 8(3):e60297. PubMed ID: 23555949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma.
    Jiang Y; Zhong B; Kawamura K; Morinaga T; Shingyoji M; Sekine I; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    BMC Cancer; 2016 Jul; 16():455. PubMed ID: 27405588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
    Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
    J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.
    Li Q; Kawamura K; Yamanaka M; Okamoto S; Yang S; Yamauchi S; Fukamachi T; Kobayashi H; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    Cancer Gene Ther; 2012 Mar; 19(3):218-28. PubMed ID: 22223137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells.
    Li Q; Kawamura K; Yang S; Okamoto S; Kobayashi H; Tada Y; Sekine I; Takiguchi Y; Shingyouji M; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    PLoS One; 2013; 8(8):e72709. PubMed ID: 23977343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
    Kuroda J; Kimura S; Segawa H; Sato K; Matsumoto S; Nogawa M; Yuasa T; Kobayashi Y; Yoshikawa T; Ottmann OG; Maekawa T
    Cancer Sci; 2004 Feb; 95(2):186-92. PubMed ID: 14965371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    Shimazu K; Tada Y; Morinaga T; Shingyoji M; Sekine I; Shimada H; Hiroshima K; Namiki T; Tatsumi K; Tagawa M
    BMC Cancer; 2017 May; 17(1):309. PubMed ID: 28464864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
    Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
    Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
    Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
    Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.
    Zhong B; Shingyoji M; Hanazono M; Nguyễn TT; Morinaga T; Tada Y; Shimada H; Hiroshima K; Tagawa M
    Apoptosis; 2020 Aug; 25(7-8):535-547. PubMed ID: 32468177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents.
    Yamanaka M; Tada Y; Kawamura K; Li Q; Okamoto S; Chai K; Yokoi S; Liang M; Fukamachi T; Kobayashi H; Yamaguchi N; Kitamura A; Shimada H; Hiroshima K; Takiguchi Y; Tatsumi K; Tagawa M
    J Thorac Oncol; 2012 Dec; 7(12):1850-1857. PubMed ID: 23154556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
    Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma.
    Cao JY; Liu L; Chen SP; Zhang X; Mi YJ; Liu ZG; Li MZ; Zhang H; Qian CN; Shao JY; Fu LW; Xia YF; Zeng MS
    Mol Cancer; 2010 Sep; 9():237. PubMed ID: 20828406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
    Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
    Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.